Holen Sie sich die Stockscreener-App
2.75
3.51%
-0.10
Vorhandelsmarkt:
2.76
0.010
+0.36%
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance - Yahoo Finance
Nkarta at stifel forum: safer cell therapy push gains traction By Investing.com - Investing.com Canada
Nkarta Stock Price Forecast. Should You Buy NKTX? - StockInvest.us
Nkarta to Participate in September Investor Conferences - Investing News Network
Two Nkarta investor talks will be webcast in September - Stock Titan
Nkarta Insiders Got A Good Deal Selling At US$2.10 - simplywall.st
Nkarta to Present Initial Autoimmune Clinical Data for - GlobeNewswire
Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders - Seeking Alpha
NKTX Q2 2026 Earnings: Deeper-than-Forecast Loss Reflects Pre-Revenue R&D InvestmentEarnings Cycle Report - dars.gov.et
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (yKkQAHM32g) - Mshale
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - Kalkine
Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX - MarketBeat
Dare Bioscience Prices $6.0 Million Registered Direct Offering - Minichart
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX) - The Globe and Mail
Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Australia
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - MarketBeat
Nkarta Inc. (NKTX) Edges Higher as Biotech Stock Holds Key Support ZoneEase of Movement - vinanet.vn
Equities Analysts Set Expectations for Nkarta Q3 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside - TradingView
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
H.C. Wainwright cuts Nkarta stock price target on trial progress By Investing.com - Investing.com Australia
NKARTA, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16 - Bitget
Nkarta, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS - MarketBeat
Nkarta Q2 EPS of $(0.54) misses $(0.38) analyst estimate - scanx.trade
Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029 - Quiver Quantitative
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aug 10 (Reuters)Nkarta Q2 Basic EPS USD -0 - Moomoo
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports 5.24% Share GainPositive Surprise Momentum - dars.gov.et
Nkarta, Inc. expected to post a loss of 38 cents a shareEarnings Preview - TradingView
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives 4.09% RallyFinal Results - dars.gov.et
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Nkarta Inc. (NKTX) Drops 2.79% to $2.09 as Key Support Level Comes into FocusLate Stage Breakouts - dars.gov.et
Nkarta (NASDAQ:NKTX) Upgraded at Wall Street Zen - MarketBeat
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss as NK Cell Therapy Pipeline AdvancesMid-Term Outlook - careplusvn.com
Nkarta, Inc. Revenue Breakdown – NASDAQ:NKTX - TradingView
NKTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Clinical Progress ContinuesBook Value Growth - careplusvn.com
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Amidst Continued Clinical ProgressSpecial Dividend Alert - careplusvn.com
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NKTX|Nkarta Inc|Price:2.920|Chg%:+0.130 - TradingKey
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nkarta Inc. (NKTX) Edges Higher: Biotech Stock Tests Key Levels After 3.5% GainGrowth ETF - dars.gov.et
Nkarta Market Sentiment - Benzinga España
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):